Sell:$5.64Buy:$6.07$0.34
(5.70%)
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment. Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism.
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.